| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Cheng-Hao Zhao, Huan Liu, Tao Pan, Zhan-Wang Xiang, Lu-Wen Mu, Jun-Yang Luo, Chu-Ren Zhou, Ming-An Li, Ming-Ming Liu, Hu-Zheng Yan and Ming-Sheng Huang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Guangzhou Science and Technology Plan Project |
No. 2023A04J0419 |
| National Natural Science Foundation Cultivation Project at the Third Affiliated Hospital of Sun Yat-sen University |
No. 2022GZRPYQN04 |
|
| Corresponding Author |
Ming-Sheng Huang, Department of Interventional Radiology, Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe Road, Guangzhou 510630, Guangdong Province, China. huangmsh@mail.sysu.edu.cn |
| Key Words |
Transarterial chemoembolization; Intrahepatic cholangiocarcinoma; Gemcitabine; Cisplatin; Idarubicin |
| Core Tip |
Intrahepatic cholangiocarcinoma (iCCA) is a liver cancer with poor survival rates and limited treatments, prompting the need for novel therapeutic strategies. This study reveals that idarubicin demonstrates superior cytotoxicity compared to standard treatments and shows improved survival outcomes when combined with gemcitabine and cisplatin in both preclinical and clinical settings. The findings highlight the potential of idarubicin-transarterial chemoembolization as a promising therapeutic agent for unresectable iCCA, offering hope for better management of this challenging disease with a manageable safety profile. |
| Publish Date |
2025-03-25 16:18 |
| Citation |
<p>Zhao CH, Liu H, Pan T, Xiang ZW, Mu LW, Luo JY, Zhou CR, Li MA, Liu MM, Yan HZ, Huang MS. Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma. <i>World J Gastrointest Oncol</i> 2025; 17(4): 103776</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i4/103776.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i4.103776 |
